Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of a Physical Exercise Program in Quality of Life of Breast Cancer Survivors (MamaMoveGaia)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04024280
Recruitment Status : Recruiting
First Posted : July 18, 2019
Last Update Posted : July 18, 2019
Sponsor:
Collaborators:
Centro Hospitalar de Vila Nova de Gaia/Espinho
Aveiro University
University Institute of Maia
Information provided by (Responsible Party):
Ana Joaquim, Associacao de Investigacao de Cuidados de Suporte em Oncologia

Brief Summary:
A 16 weeks 3-weekly supervised and adapted physical exercise program will be applied to breast cancer survivors in surveillance and, in estrogen receptor positive cases, under hormonotherapy. The program will be applied in group classes of 20 participants, in the facilities of one local gymnasium, by fitness instructors included in the investigation team. Investigators will evaluate the Health-Related Quality of Life (HRQoL), physical activity, cardiopulmonary fitness, upper limb strength and lower limb functionality. The investigators also aim to evaluate the safety of the program and oncological outcomes such as symptoms related to disease and its treatment and, also, overall survival and disease free survival.

Condition or disease Intervention/treatment Phase
Breast Cancer Quality of Life Physical Exercise Other: Physical exercise program Not Applicable

Detailed Description:
This protocol describes a two-arm prospective non randomized trial that will test the HRQoL effect of a 16 weeks 3-weekly supervised and adapted physical exercise program that combines muscle strength and aerobic training with progressive intensity. The benefits of physical exercise programs in breast cancer survivors is well known. However, the studied programs usually are not generalizable because of needs of specialized exercise professionals and materials. The investigators aim to evaluate if it is possible to obtain the same benefits in HRQoL, physical activity, cardiopulmonary fitness, upper limb strength and lower limb functionality when the program is applied in group classes by trained fitness instructors with exercise strategies based in limited material. Maximum participants of each group class is 20. Each participant will pass through a 16 weeks control phase, during which should maintain the usual physical activity and, then, through a 16 weeks study phase, during which undergoes the physical exercise program. In each phase, the participants will be serially evaluated. During the 32 weeks, each participant will pass through 5 evaluation moments: at baseline, at 8 weeks, at 16 weeks before beginning the study phase, at 8 weeks of physical exercise and 16 weeks of physical exercise at the end of the program. After, investigators aim to evaluate each participant at 3, 6 and 12 months ant, then, yearly.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Effects of a Physical Exercise Program in Quality of Life of Breast Cancer Survivors
Actual Study Start Date : July 1, 2018
Estimated Primary Completion Date : June 2020
Estimated Study Completion Date : June 2021


Arm Intervention/treatment
Experimental: Intervention arm
Patients will perform a supervised physical exercise program specifically developed for breast cancer patients, based on the guidelines of the American College of Sports Medicine. The physical exercise program comprises 3 weekly sessions of 60 minutes each. Each session will involve an initial warm-up with light mobility exercises, followed by resistance and aerobic training and ending with a return to calm phase of light stretching exercises.
Other: Physical exercise program
Frequency: 3 weekly sessions. Intensity of aerobic training: reporting 12-17 in the Borg scale. Time of aerobic training: 10 minutes in the first and second weeks and then 2 added minutes at each 2 weeks. Type of aerobic training: walking and stepping. Intensity of resistance training: without load in the first week and, then, 15 submaximal repetitions. Time of resistance training: 30 minutes. Type of resistance training: using free weights; the lower body exercises will be squat, leg extension, leg curl and calf raise; the upper body exercises will be frontal and lateral arm raise, chest press, seated row and bicep curl.

No Intervention: Control arm
Patients should maintain the usual physical activity



Primary Outcome Measures :
  1. Health Related Quality of Life [ Time Frame: Baseline ]
    European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core-30 (QLQ-C30). This is a patient-reported questionnaire composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items. All of the scales and single-item measures range in score from 0 to 100.A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.

  2. Health Related Quality of Life [ Time Frame: Week 8 ]
    European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core-30 (QLQ-C30). This is a patient-reported questionnaire composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items. All of the scales and single-item measures range in score from 0 to 100.A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.

  3. Health Related Quality of Life [ Time Frame: Week 16 ]
    European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core-30 (QLQ-C30). This is a patient-reported questionnaire composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items. All of the scales and single-item measures range in score from 0 to 100.A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.

  4. Health Related Quality of Life [ Time Frame: Week 24 ]
    European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core-30 (QLQ-C30). This is a patient-reported questionnaire composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items. All of the scales and single-item measures range in score from 0 to 100.A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.

  5. Health Related Quality of Life [ Time Frame: Week 32 ]
    European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core-30 (QLQ-C30). This is a patient-reported questionnaire composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items. All of the scales and single-item measures range in score from 0 to 100.A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histological diagnosis of breast carcinoma
  • Stages 0 to IIIC
  • Having undergo primary treatment with curative intent, defined as surgery that can have been complemented with neoadjuvant, or adjuvant, chemotherapy and/or radiotherapy
  • Conclusion of the last of the following treatments at least one month before: surgery, chemotherapy or radiotherapy
  • At least one consultation in the Medical Oncology Department of the Centro Hospitalar de Vila Nova de Gaia/Espinho
  • Assistant medical oncologist consent for the physical exercise practice
  • Not meeting the physical activity guidelines of the American College of Sports Medicine (moderate activity ≥ 150 minutes/week ou vigorous activity ≥ 75 minutes/week and ≥ 2 resistance training/week).

Exclusion Criteria:

  • Severe anemia (Hb ≤ 8 g/dL)
  • Symptomatic moderate anemia (Hb >8 and ≤ 10 g/dL); considered symptoms are: sustained tachycardia, exertion dyspnea, thoracic pain or syncope
  • Uncontrolled hypertension
  • Uncontrolled diabetes
  • Cardiac failure grade >1 in the New York Heart Association evaluation
  • History of osteoporosis with Tscore <-2.5 in the lumbar spine and/or femur in the menopause
  • Contraindication given by the assistant surgeon

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04024280


Contacts
Layout table for location contacts
Contact: Ana Joaquim, MD +351966867546 anaisabeljoaquim@gmail.com
Contact: Pedro Antunes, MSc +351969270946 pantunes_14@hotmail.com

Locations
Layout table for location information
Portugal
Centro Hospitalar de Vila Nova de Gaia/Espinho Recruiting
Vila Nova de Gaia, Oporto, Portugal, 4434-502 Vila Nova de Gaia
Contact: Ana Joaquim, MD    +351966867546    anaisabeljoaquim@gmail.com   
Contact: Pedro Antunes, MSc    +351969270946    pantunes_14@hotmail.com   
Sub-Investigator: Luísa Helguero, PhD         
Sub-Investigator: Horácio Costa, PhD         
Sub-Investigator: Alberto Alves, PhD         
Sub-Investigator: Anabela Amarelo, RN         
Sub-Investigator: Bárbara Duarte, MSc         
Sub-Investigator: Micael Vieira, MSc         
Sub-Investigator: Catarina Garcia, MSc         
Sub-Investigator: Pedro Antunes, MSc         
Principal Investigator: Ana Joaquim, MD         
Sponsors and Collaborators
Associacao de Investigacao de Cuidados de Suporte em Oncologia
Centro Hospitalar de Vila Nova de Gaia/Espinho
Aveiro University
University Institute of Maia
Investigators
Layout table for investigator information
Principal Investigator: Ana Joaquim, MD Centro Hospitalar de Vila Nova de Gaia/Espinho

Layout table for additonal information
Responsible Party: Ana Joaquim, Principal investigator, Associacao de Investigacao de Cuidados de Suporte em Oncologia
ClinicalTrials.gov Identifier: NCT04024280     History of Changes
Other Study ID Numbers: MAMA_MOVE_Gaia After Treatment
First Posted: July 18, 2019    Key Record Dates
Last Update Posted: July 18, 2019
Last Verified: July 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases